Cardiovascular disease supplements refer to nutritional products designed to complement traditional approaches in managing cardiovascular health. These supplements typically contain a variety of vitamins, minerals, antioxidants, and other bioactive compounds that are believed to support heart health. Common cardiovascular disease supplements include omega-3 fatty acids, coenzyme Q10 (CoQ10), magnesium, vitamin D, and various antioxidants such as vitamin C and E. Omega-3 fatty acids, found in fish oil supplements, are often associated with reducing triglycerides and inflammation, while CoQ10 plays a role in cellular energy production. These supplements are commonly taken by individuals aiming to enhance their cardiovascular health, either as part of preventive measures or in conjunction with prescribed medications. It's crucial for individuals considering cardiovascular disease supplements to consult with healthcare professionals, as the effectiveness and safety of these supplements may vary, and potential interactions with medications should be carefully evaluated.
Title : Personalized and precision medicine (PPM) as a unique healthcare model through biodesign-driven translational applications and cardiology-related healthcare marketing to secure the human healthcare and biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Beyond weight loss and diabetes control GLP 1 agonists paradigm shift in Cardiovascular care .
Syed Raza, Awali Hospital, Bahrain
Title : Vericiguat Inhibits the Progress of Cardiac Hypertrophy and Prevents Hypertrophy Induced Heart Failure by Multiple Mechanisms
Guo Wei He, TEDA International Cardiovascular Hospital, Tianjin University, China
Title : Coronary revascularization in patients with diabetes: Prospects for stenting in patients with type 1 diabetes and coronary artery disease
Mekhman N Mamedov, National Research Center for Therapy and Preventive Medicine, Russian Federation
Title : STEMI versus acute occlusive myocardial infarction: Which term should we use?
Yochai Birnbaum, Baylor College of Medicine, United States
Title : Chronic angina and the health economics of cardiovascular risk reduction in macro- and microvascular coronary disease
Uwe Peter Tigor, Auxilius Pharma, United States